**Author's contributions**

X.Z. conceived the concept, designed the manuscript, wrote and critically revised the manuscript, coordinated and was responsible for the correspondence work and financial support. N.L. participated in preparing figures, and partial literature analysis.

### **Acronyms and abbreviations**


**4. Conclusions**

**Figure 8.**

**230**

**Figure 7.**

Ivermectin, as an old, common, and classic anti-parasite drug, has demonstrated its effective *in vitro* anti-cancer efficiency for ovarian cancer. Ivermectin significantly inhibited cell proliferation, growth and migration, blocked cell cycle progression,

*Lasso regression identified and optimized the prognostic model of ivermectin-related three-lncRNA signature in ovarian cancers. (A and B). Lasso regression complexity is controlled by lambda using the glmnet R package. (C). Overall survival analysis of three-lncRNA signature between high-risk and low-risk groups. Reproduced*

*from Li et al. [4], with copyright permission from nature springer publisher, copyright 2020.*

*RT-qPCR analysis revealed the effects of ivermectin on lncRNAs in ovarian cancers relative to control cells. Reproduced from Li et al. [4], with copyright permission from nature springer publisher, copyright 2020.*

*Ovarian Cancer - Updates in Tumour Biology and Therapeutics*

**References**

jcp.30055.

e10.

**233**

[1] Burg RW, Miller BM, Baker EE, et al. Avermectins, new family of potent anthelmintic agents: producing

*DOI: http://dx.doi.org/10.5772/intechopen.95556*

*The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer*

[10] Li N, Zhan X. Mass spectrometrybased mitochondrial proteomics in human ovarian cancer. Mass Spectrom

[11] Li N, Zhan X. Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics. EPMA J

Rev 2020; 39(5–6): 471–498.

[12] Li N, Li H, Cao L, Zhan X. Quantitative analysis of the mitochondrial proteome in human ovarian carcinomas. Endocr Relat Cancer 2018; 25(10): 909–931.

[13] Li N, Li J, Desiderio DM, Zhan X. SILAC quantitative proteomics analysis

of vermectin-related proteomic profiling and molecular network alterations in human ovarian cancer cells. J Mass Spectrom 2020; e4659. DOI:

[14] Zhang X, Qin T, Zhu Z, et al. Ivermectin augments the in vitro and in vivo efficacy of cisplatin in epithelial ovarian cancer by suppressing Akt/ mTOR signaling. Am J Med Sci 2020;

[15] Hashimoto H, Messerli SM, Sudo T, Maruta H. Ivermectin inactivates the kinase PAK1 and blocks the PAK1 dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther 2009; 3(6): 243–246.

[16] Dou Q, Chen HN, Wang K, et al. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Cancer Res 2016; 76(15): 4457–

[17] Song D, Liang H, Qu B, et al. Ivermectin inhibits the growth of glioma cells by inducing cell cycle arrest and apoptosis in vitro and in vivo. J Cell

Biochem 2019; 120(1): 622–633.

10.1002/jms.4659.

359(2): 123–129.

4469.

2019; 10(2): 153–172.

organism and fermentation. Antimicrob Agents Chemother 1979; 15(3): 361–367.

[2] Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. J Antibiot (Tokyo) 2017; 70(5): 495–505.

[3] Laing R, Gillan V, Devaney E. Ivermectin—old drug, new tricks? Trends Parasitol 2017; 33(6): 463–472.

[4] Li N, Zhan X. Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes. EPMA J 2020; 11(2): 289–309.

[5] Li N, Zhao L, Zhan X. Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol 2020. DOI: 10.1002/

[6] Liu J, Zhang K, Cheng L, Zhu H, Xu T. Progress in understanding the molecular mechanisms underlying the antitumour effects of ivermectin. Drug Des Devel Ther 2020; 14: 285–296.

[7] Juarez M, Schcolnik-Cabrera A, Duenas-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res 2018; 8(2): 317–331.

[8] Kobayashi Y, Banno K, Kunitomi H, Tominaga E, Aoki D. Current state and

outlook for drug repositioning anticipated in the field of ovarian cancer. J Gynecol Oncol 2019; 30(1):

[9] Triarico S, Capozza MA,

Mastrangelo S, Attinà G, Maurizi P, Ruggiero A. Gynecological cancer among adolescents and young adults (AYA). Ann Transl Med 2020; 8(6): 397.
